Dermata Therapeutics Stock Analysis
DRMA Stock | USD 1.14 0.01 0.87% |
Dermata Therapeutics is undervalued with Real Value of 23.34 and Target Price of 90.0. The main objective of Dermata Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Dermata Therapeutics is worth, separate from its market price. There are two main types of Dermata Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Dermata Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Dermata Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
Dermata |
Dermata Stock Analysis Notes
The company has price-to-book (P/B) ratio of 0.49. Some equities with similar Price to Book (P/B) outperform the market in the long run. Dermata Therapeutics recorded a loss per share of 13.36. The entity had not issued any dividends in recent years. The firm had 1:15 split on the 16th of May 2024. Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company was incorporated in 2014 and is headquartered in San Diego, California. Dermata Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 8 people. To learn more about Dermata Therapeutics call the company at 858 800 2543 or check out https://www.dermatarx.com.Dermata Therapeutics Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Dermata Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Dermata Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Dermata Therapeutics generated a negative expected return over the last 90 days | |
Dermata Therapeutics has high historical volatility and very poor performance | |
Dermata Therapeutics may become a speculative penny stock | |
Dermata Therapeutics has a very high chance of going through financial distress in the upcoming years | |
Net Loss for the year was (7.79 M) with profit before overhead, payroll, taxes, and interest of 0. | |
Dermata Therapeutics currently holds about 10.63 M in cash with (6.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.05. | |
Dermata Therapeutics has a frail financial position based on the latest SEC disclosures | |
Latest headline from gurufocus.com: ARMISTICE CAPITAL, LLC Increases Stake in Dermata Therapeutics Inc |
Dermata Therapeutics Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Dermata Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
20th of February 2024 Upcoming Quarterly Report | View | |
9th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
20th of February 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Dermata Largest EPS Surprises
Earnings surprises can significantly impact Dermata Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2023-11-09 | 2023-09-30 | -0.63 | -0.54 | 0.09 | 14 | ||
2023-08-10 | 2023-06-30 | -0.92 | -0.63 | 0.29 | 31 | ||
2023-05-11 | 2023-03-31 | -2.65 | -2.27 | 0.38 | 14 |
Dermata Therapeutics Thematic Classifications
In addition to having Dermata Therapeutics stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Pharmaceutical ProductsUSA Equities from Pharmaceutical Products industry as classified by Fama & French |
Dermata Stock Institutional Investors
Shares | Tower Research Capital Llc | 2024-06-30 | 1.7 K | Ubs Group Ag | 2024-06-30 | 1.7 K | Wells Fargo & Co | 2024-06-30 | 45.0 | Bank Of America Corp | 2024-06-30 | 3.0 | Acadian Asset Management Llc | 2024-06-30 | 0.0 | Geode Capital Management, Llc | 2024-06-30 | 0.0 | Armistice Capital, Llc | 2024-09-30 | 0.0 | Two Sigma Securities, Llc | 2024-06-30 | 0.0 | Northwestern Mutual Wealth Management Co | 2024-06-30 | 0.0 |
Dermata Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.32 M.Dermata Profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.98) | (1.03) | |
Return On Capital Employed | (1.27) | (1.33) | |
Return On Assets | (0.98) | (1.03) | |
Return On Equity | (1.23) | (1.29) |
Management Efficiency
Dermata Therapeutics has return on total asset (ROA) of (0.9068) % which means that it has lost $0.9068 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.7301) %, meaning that it created substantial loss on money invested by shareholders. Dermata Therapeutics' management efficiency ratios could be used to measure how well Dermata Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 25, 2024, Return On Tangible Assets is expected to decline to -1.03. In addition to that, Return On Capital Employed is expected to decline to -1.33. At present, Dermata Therapeutics' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Debt To Assets is expected to grow to 5.53, whereas Total Assets are forecasted to decline to about 6.4 M.Last Reported | Projected for Next Year | ||
Book Value Per Share | 32.76 | 34.40 | |
Tangible Book Value Per Share | 32.76 | 34.40 | |
Enterprise Value Over EBITDA | (20.62) | (21.65) | |
Price Book Value Ratio | 0.28 | 0.29 | |
Enterprise Value Multiple | (20.62) | (21.65) | |
Price Fair Value | 0.28 | 0.29 | |
Enterprise Value | 70.8 M | 67.2 M |
Dermata Therapeutics has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Beta 0.792 | Return On Assets (0.91) | Return On Equity (1.73) |
Technical Drivers
As of the 25th of November, Dermata Therapeutics shows the Mean Deviation of 4.98, variance of 69.11, and Standard Deviation of 8.31. Dermata Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.Dermata Therapeutics Price Movement Analysis
The output start index for this execution was eleven with a total number of output elements of fifty. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Dermata Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Dermata Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Dermata Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Dermata Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Dermata Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Dermata Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Scott Kathleen D. over six months ago Acquisition by Scott Kathleen D. of 10000 shares of Dermata Therapeutics at 0.6099 subject to Rule 16b-3 | ||
Sandler Andrew Seth over six months ago Acquisition by Sandler Andrew Seth of 5000 shares of Dermata Therapeutics at 1.88 subject to Rule 16b-3 | ||
Gerald Proehl over six months ago Acquisition by Gerald Proehl of 27987 shares of Dermata Therapeutics at 20.5 subject to Rule 16b-3 | ||
Gerald Proehl over six months ago Dermata Therapeutics exotic insider transaction detected | ||
Nardo Christopher J over a year ago Acquisition by Nardo Christopher J of 100000 shares of Dermata Therapeutics subject to Rule 16b-3 |
Dermata Therapeutics Outstanding Bonds
Dermata Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Dermata Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Dermata bonds can be classified according to their maturity, which is the date when Dermata Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Boeing Co 2196 Corp BondUS097023DG73 | View | |
HSBC Holdings PLC Corp BondUS404280DR76 | View |
Dermata Therapeutics Predictive Daily Indicators
Dermata Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Dermata Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Dermata Therapeutics Forecast Models
Dermata Therapeutics' time-series forecasting models are one of many Dermata Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Dermata Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Dermata Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Dermata Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Dermata shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Dermata Therapeutics. By using and applying Dermata Stock analysis, traders can create a robust methodology for identifying Dermata entry and exit points for their positions.
Last Reported | Projected for Next Year |
Current Dermata Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Dermata analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Dermata analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
90.0 | Buy | 1 | Odds |
Most Dermata analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Dermata stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Dermata Therapeutics, talking to its executives and customers, or listening to Dermata conference calls.
Dermata Stock Analysis Indicators
Dermata Therapeutics stock analysis indicators help investors evaluate how Dermata Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Dermata Therapeutics shares will generate the highest return on investment. By understating and applying Dermata Therapeutics stock analysis, traders can identify Dermata Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow | 6.2 M | |
Common Stock Shares Outstanding | 195 K | |
Total Stockholder Equity | 6.4 M | |
Cash And Short Term Investments | 7.4 M | |
Cash | 7.4 M | |
Accounts Payable | 866 K | |
Net Debt | -7.4 M | |
50 Day M A | 1.4362 | |
Total Current Liabilities | 1.6 M | |
Other Operating Expenses | 8 M | |
Stock Based Compensation | 522.1 K |
Complementary Tools for Dermata Stock analysis
When running Dermata Therapeutics' price analysis, check to measure Dermata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dermata Therapeutics is operating at the current time. Most of Dermata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dermata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dermata Therapeutics' price. Additionally, you may evaluate how the addition of Dermata Therapeutics to your portfolios can decrease your overall portfolio volatility.
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
CEOs Directory Screen CEOs from public companies around the world | |
Commodity Directory Find actively traded commodities issued by global exchanges |